Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy

BACKGROUND: Cancer immunotherapy has generated significant excitement, mainly as a result of the development of immune checkpoint inhibitors. The blockade of PD-1 or its ligand with antibodies has resulted in impressive clinical efficacy. However, a subset of patients does not respond to biologic th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jing, Chen, Chen, Ju, Rui, Wang, Qingzhu, Li, Juan, Guo, Lei, Ye, Caiying, Zhang, Dechang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740021/
https://www.ncbi.nlm.nih.gov/pubmed/31511064
http://dx.doi.org/10.1186/s40425-019-0725-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740021/
https://www.ncbi.nlm.nih.gov/pubmed/31511064
http://dx.doi.org/10.1186/s40425-019-0725-7

Ejemplares similares